Pharma & Biotech Mergers & Acquisitions News
Biotechnology
California-based clinical-stage biotech Tempest Therapeutics has announced that the company plans to explore a full range of strategic alternatives to advance its promising clinical stage programs and maximize stockholder value. 10 April 2025
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
Speaking at the companys annual meeting, Swiss drug maj'or Roche (ROG: SIX) chairman Franz Humer said: "Our strategy of concentrating on pharmaceuticals and diagnostics and our sharp focus on innovation will also be key for our future success. The proposed acquisition of Illumina would strengthen our Diagnostics Division because gene sequencing will be a key technology going forward. Roche and Illumina would benefit from a rapid merger. However, this is an area where we have other options should the transaction fail over price." 7 March 2012
Pharmaceutical
In a second acquisition within six months, UK-based protein research tools supplier Abcam (AIM: ABC) has entered into a definitive agreement to buy Epitomics International, an antibody business headquartered in San Francisco, California, USA, with operations in China, for a gross consideration of $170.0 million. 6 March 2012
Pharmaceutical
As part of a series of strategic moves to build its laboratory information management system (LIMS) business in Europe and emerging markets in Latin America and Africa, STARLIMS Technologies, a subsidiary of US health care major Abbott (NYSE: ABT), has announced the acquisition of several longtime distribution partners. 4 March 2012
Pharmaceutical
UK pharma giant GlaxoSmithKline (LSE: GSK) says it has signed an agreement with Japan's third-largest drugmaker Daiichi Sankyo (TYO: 4568) to form a joint venture (JV) which is expected to create the number one vaccines company in Japan. Completion of the transaction is expected in the third quarter of this year, subject to local regulatory approvals. 2 March 2012
Pharmaceutical
Germany's Bayer (BAY: DE) is still confident that it can become a top-10 gobal pharmaceutical company, given its strong R&D pipeline with four potential blockbusters and also some acquisitions, the firm's chief executive, Marijn Dekkers, told journalists at the annual financial results conference in Leverkusen this week 1 March 2012
Pharmaceutical
Danish CNS drug specialist Lundbeck A/S (LUND: DC) and Germany's Paion AG (FSE: PA8) have entered into a definitive agreement under which Lundbeck acquires all of Paion's remaining rights to desmoteplase currently under clinical Phase III development for ischemic stroke. 29 February 2012
Pharmaceutical
Roche has extended its $5.7 billion hostile takeover offer for genetic sequencing specialist Illumina by a month, but has not chosen to increase its bid from the current level of $44.50 per share. 28 February 2012
Pharmaceutical
New Jersey, USA-based botanical therapeutics company Herborium (Pink Sheets: HBRM) says it has signed a Letter of Intent with China Health Resource (OTCBB CHRI) for the sale of up to a 100% interest in Herborium. 26 February 2012
Pharmaceutical
New upcoming treatments for Cushing's syndrome promise to improve patient's quality of life, according to a new report from pharmaceutical intelligence company GlobalData, which found that Cushing's syndrome patients can expect increasingly safe and effective pharmaceutical treatment options in the future, due to the expected launch of three late-stage pipeline molecules. 22 February 2012
Pharmaceutical
David Balto, an antitrust attorney in Washington DC, USA, and former Policy Director of the Federal Trade Commission, released a white paper yesterday exposing the flaws in efficiency claims made by US pharmacy benefit managers (PBMs) Express Scripts (Nasdaq: ESRX) and Medco Health Solutions (NYSE: MHS), with respect to their proposed merger. 20 February 2012
Pharmaceutical
Japan's Maruho says it has acquired Cutanea Life Sciences (CLS), a privately held dermatology development company based in Villanova, Pennsylvania, USA. CLS will become a wholly-owned subsidiary of Maruho. 15 February 2012
Pharmaceutical
German drugmaker Riemser Arzneimittel AG is extending its range of supportive cancer therapy products by purchasing the world-wide rights to Swiss drug major Roche's (ROG: SIX) Ostac (clodronic acid), a drug used in chemotherapy regimens for the treatment of metastatic bone lesions. Financial terms of the deal were not disclosed. 15 February 2012
Pharmaceutical
USA-based regenerative wound care specialist Cytomedix (OTC.BB: CMXI.OB) said yesterday that it has completed the acquisition of Aldagen, a privately-held US biopharmaceutical company developing regenerative cell therapies based on its proprietary ALDH bright cell (ALDHbr) technology, which has twice dropped an initial public offering (IPO) because of negative market conditions. 10 February 2012
Pharmaceutical
Having thoroughly reviewed Swiss drug and diagnostics major Roche's (ROG: SIX) hostile takeover bid, USA-based Illumina (Nasdaq: ILMN) says its board of directors has unanimously determined that the unsolicited $44.50 per share - around $5.7 billion in total - cash offer (The Pharma Letter January 25) is 'grossly inadequate in multiple respects, dramatically undervalues Illumina and is contrary to the best interests of Illumina's stockholders.' 8 February 2012
Pharmaceutical
Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) says that it has withdrawn its increased offer to acquire US ophthalmic and allergy specialist ISTA Pharmaceuticals (Nasdaq: ISTA) for $7.50 per share in cash. 31 January 2012
Pharmaceutical
Responding to Swiss drug major Roche's (ROG: SIX) hostile takeover over offer of $44.50 per share for US DNA sequencing firm Illumina (Nasdaq: ILMN) the latter has agreed to review the proposal valuing the company at around $5.7 billion and come up with recommendations to shareholders in due course (The Pharma Letter January 25). 27 January 2012
Pharmaceutical
USA-based Spectrum Pharmaceuticals (NasdaqGS: SPPI) says it has entered into an agreement to acquire licensing rights to market Zevalin (ibritumomab tiuxetan) injection for intravenous use outside of the USA from Bayer Healthcare, a unit of Germany's Bayer AG (BAY: DE). Financial terms of the transaction were not revealed. 26 January 2012
Pharmaceutical
Swiss drugs and diagnostic major Roche (ROG: SIX) announced this morning that it is proposing to acquire all outstanding shares of Illumina, (Nasdaq: ILMN), a USA-based provider of integrated systems for DNA sequencing, for $44.50 per share in cash, or an aggregate of approximately $5.7 billion on a fully diluted basis. The Roche moves comes despite the US firm's reluctance to enter discussions. 25 January 2012
Pharmaceutical
Florida, USA-based OPKO Health (NYSE: OPK) had a busy day yesterday, entering into a definitive agreement to acquire ALS Distribuidora Limitada (ALS), a privately-held Chilean pharmaceutical company engaged in the business of importation, commercialization and distribution of pharmaceutical products for private markets, as well as gaining exclusive rights to two biomarkers from a Finnish company. 24 January 2012
Pharmaceutical
California, USA-based XOMA Corp (Nasdaq: XOMA) says it has acquired US rights to the perindopril franchise from France's Laboratoires Servier, XOMA's partner for its lead product candidate, gevokizumab (formerly XOMA 052), which failed in mid-stage trials but is now being studied by the US firm as an acne treatment and for the non-infectious form of the eye disease uveitis. 18 January 2012
Pharmaceutical
US biotech start-up RayThera has secured $110 million in series A financing to fund the early clinical development of its small molecule drug candidates in immunology. 8 April 2025
Pharmaceutical
US private equity firm Vance Street Capital has expanded its life sciences manufacturing platform with the acquisition of Irish contract manufacturer Zenith Adhesive Components, adding further technical capabilities and boosting regional reach. 4 April 2025
Pharmaceutical
Plenty of money changed hands in pharma M&A during March, with the biggest deal a $6.7 billion merger between Mallinckrodt Pharmaceuticals and Endo, after the pair emerged from bankruptcy processes linked to liabilities over the US opioid crisis. 2 April 2025
Pharmaceutical
Japanese drugmaker Sumitomo Pharma said yesterday that it is divesting its Asian business to major Japanese trading house Marubeni for roughly 72 billion yen ($480 million) in a deal that forms part of its post-Latuda (lurasidone) turnaround efforts. 2 April 2025
Pharmaceutical
Florida-based MIRA Pharmaceuticals, a pharma company developing therapeutics for neurologic and neuropsychiatric disorders, has signed a binding letter of intent (LOI) to acquire privately held Delaware firm SKNY Pharmaceuticals. 24 March 2025
Pharmaceutical
Privately-held drugmaker Paratek Pharmaceuticals is to buy specialty pharma Optinose, including its approved product Xhance (fluticasone propionate). 20 March 2025
Pharmaceutical
Chinese pharmaceutical company Fosun Pharmaceutical Group has agreed to sell its stake in private hospital operator United Family Healthcare to an investment firm owned by US private equity giant Warburg Pincus. 14 March 2025
Pharmaceutical
USA-based Azurity Pharmaceuticals says it has completed its acquisition of Covis Group from existing investors and the privately-held Swiss drugmaker is now a wholly-owned subsidiary of Azurity. 14 March 2025
Pharmaceutical
Ireland-based Mallinckrodt Pharmaceuticals and Endo Inc have agreed to combine in a stock and cash deal worth $6.7 billion, after the pair emerged from bankruptcy processes linked to liabilities over the US opioid crisis. 13 March 2025
Pharmaceutical
Alliance Pharma has accepted a final increased cash offer from investment firm DBAY Advisors, valuing the UK-based pharmaceutical company at approximately £362 million ($468 million). 11 March 2025
Pharmaceutical
USA-based Endo Inc today announced it has entered into a definitive agreement to divest its international pharmaceuticals business, primarily operated through Canada-based specialty pharmaceutical company Paladin Pharma to Knight Therapeutics. 11 March 2025
Pharmaceutical
Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and AstraZeneca. US pharma major AbbVie became the latest entrant to the weight management sector, striking a deal with Gubra for its obesity candidate GUB14295. On the M&A front, Ireland-headquartered Jazz Pharmaceuticals announced it is acquiring Chimerix for around $935 million to expand its oncology portfolio. USA-based scPharmaceuticals gained US Food and Administration (FDA) approval for its supplemental new drug application (sNDA) for Furoscix in chronic kidney disease (CKD). 9 March 2025
Pharmaceutical
Private equity firms acquiring assets were among the most eye-catching deals in pharma M&A during February. 6 March 2025
Pharmaceutical
Ireland-headquartered Jazz Pharmaceuticals has entered into a definitive agreement to acquire US biopharma company Chimerix for $8.55 per share in cash, representing a total consideration of around $935 million. The news sent Chimerix’ shares rocketing almost 70% to $8.40. 5 March 2025
Pharmaceutical
French biotech start-up studio Argobio and non-profit biomedical research center the Institut Pasteur have announced the launch of Enodia Therapeutics. 26 February 2025
Pharmaceutical
Kelso Pharma, the British specialty pharma business backed by Apposite Capital, today announced the acquisition of the UK pharma business, Alturix Holdings Limited. Financial terms were not disclosed. 24 February 2025
Pharmaceutical
US drugmaker Cosette Pharmaceuticals has entered into a definitive agreement to acquire all the outstanding shares of Australia-based Mayne Pharma with the aim of expanding its health portfolio. 21 February 2025
Pharmaceutical
FibroGen today announced the sale of its China subsidiary to UK pharma major AstraZeneca for around $160 million, with the news sending the California-based company’s shares soaring 27% to $0.71. 20 February 2025
Pharmaceutical
An Expert View from Nick Petschek, EMEA managing director at global change management firm Kotter International. 12 February 2025
Pharmaceutical
Caymen Islands-headquartered specialty drug firm Legacy Pharma has announced the completion of the acquisition of InterMune, along with the intellectual property rights to Esbriet (pirfenidone) in the USA, from Genentech, a subsidiary of Swiss pharma giant Roche. 11 February 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze